Leonteq Securities AG Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN

Leonteq Securities AG acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,342 shares of the biopharmaceutical company’s stock, valued at approximately $1,036,000.

A number of other hedge funds have also recently added to or reduced their stakes in REGN. Brighton Jones LLC lifted its position in Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock valued at $675,000 after purchasing an additional 686 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in Regeneron Pharmaceuticals in the first quarter valued at about $226,000. Arrowstreet Capital Limited Partnership acquired a new stake in Regeneron Pharmaceuticals in the second quarter valued at about $3,183,000. Gabelli Funds LLC lifted its position in Regeneron Pharmaceuticals by 3.0% in the second quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company’s stock valued at $978,000 after purchasing an additional 55 shares during the period. Finally, Sei Investments Co. lifted its position in Regeneron Pharmaceuticals by 18.8% in the second quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company’s stock valued at $16,985,000 after purchasing an additional 5,120 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of recent analyst reports. Royal Bank Of Canada reduced their price objective on shares of Regeneron Pharmaceuticals from $762.00 to $707.00 and set a “sector perform” rating for the company in a research report on Monday. Citigroup cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the company from $900.00 to $700.00 in a report on Monday. Guggenheim increased their target price on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a report on Friday, May 1st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Friday, March 27th. Finally, Zacks Research cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $792.65.

Regeneron Pharmaceuticals Trading Down 1.1%

Shares of REGN opened at $642.59 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The firm has a 50 day simple moving average of $734.17 and a 200-day simple moving average of $745.67. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The stock has a market cap of $67.93 billion, a price-to-earnings ratio of 15.66, a price-to-earnings-growth ratio of 1.43 and a beta of 0.30.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping the consensus estimate of $8.91 by $0.56. The firm had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. Regeneron Pharmaceuticals’s revenue for the quarter was up 19.0% on a year-over-year basis. During the same period in the previous year, the company earned $8.22 EPS. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.25 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th will be paid a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $705.24, for a total value of $70,524.00. Following the completion of the sale, the director directly owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. The trade was a 0.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron said its Lynozyfic (linvoseltamab) Phase 1/2 LINKER-AL2 trial in systemic AL amyloidosis produced rapid and deep responses, including free light chain normalization by day 15 and a 100% hematologic complete response rate at the highest dose, with signs of organ-function improvement. Article Title
• Neutral Sentiment: The Lynozyfic data could strengthen Regeneron’s hematology pipeline over time, but the treatment is still investigational for AL amyloidosis and the trial included safety issues such as infections, neutropenia and cytokine release syndrome. Article Title
• Neutral Sentiment: Regeneron also announced a milestone in its REGN7544 sepsis-induced hypotension study, adding another positive update from the pipeline, though the commercial impact is still uncertain. Article Title
• Negative Sentiment: Sentiment has been pressured by Regeneron’s recent disclosure that its Phase 3 melanoma trial for fianlimab plus Libtayo failed to meet its primary endpoint, raising concerns about the company’s near-term oncology prospects. Article Title
• Negative Sentiment: Multiple law firms have opened securities investigations tied to the melanoma trial miss, which can add overhang and keep traders cautious on REGN. Article Title

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.